Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.

BACKGROUND & AIMS:Activation of the renin-angiotensin-system is known to play a role in nonalcoholic steatohepatitis. Renin knockout mice manifest decreased hepatic steatosis. Aliskiren is the first direct renin inhibitor to be approved for clinical use. Our study aims to evaluate the possible t...

Full description

Bibliographic Details
Main Authors: Kuei-Chuan Lee, Che-Chang Chan, Ying-Ying Yang, Yun-Cheng Hsieh, Yi-Hsiang Huang, Han-Chieh Lin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3804600?pdf=render
id doaj-9cdb5d76a918456e940cb5bf46eb7b62
record_format Article
spelling doaj-9cdb5d76a918456e940cb5bf46eb7b622020-11-25T01:19:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01810e7781710.1371/journal.pone.0077817Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.Kuei-Chuan LeeChe-Chang ChanYing-Ying YangYun-Cheng HsiehYi-Hsiang HuangHan-Chieh LinBACKGROUND & AIMS:Activation of the renin-angiotensin-system is known to play a role in nonalcoholic steatohepatitis. Renin knockout mice manifest decreased hepatic steatosis. Aliskiren is the first direct renin inhibitor to be approved for clinical use. Our study aims to evaluate the possible therapeutic effects and mechanism of the chronic administration of aliskiren in a dietary steatohepatitis murine model. METHODS:Male C57BL/6 mice were fed with a methionine and choline-deficient (MCD) diet to induce steatohepatitis. After 8 weeks of feeding, the injured mice were randomly assigned to receive aliskiren (50 mg·kg(-1) per day) or vehicle administration for 4 weeks. Normal controls were also administered aliskiren (50 mg·kg(-1) per day) or a vehicle for 4 weeks. RESULTS:In the MCD mice, aliskiren attenuated hepatic steatosis, inflammation and fibrosis. Aliskiren did not change expression of lipogenic genes but increase turnover of hepatic fat by up-regulating peroxisome proliferator-activated receptor α, carnitine palmitoyltransferase 1a, cytochrome P450-4A14 and phosphorylated AMP-activated protein kinase. Furthermore, aliskiren decreased the hepatic expression of angiotensin II and nuclear factor κB. The levels of oxidative stress, hepatocyte apoptosis, activation of Kupffer cells and hepatic stellate cells, and pro-fibrotic markers were also reduced in the livers of the MCD mice receiving aliskiren. CONCLUSIONS:Aliskiren attenuates steatohepatitis and fibrosis in mice fed with a MCD diet. Thus, the noted therapeutic effects might come from not only the reduction of angiotensin II but also the up-regulation of fatty acid oxidation-related genes.http://europepmc.org/articles/PMC3804600?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Kuei-Chuan Lee
Che-Chang Chan
Ying-Ying Yang
Yun-Cheng Hsieh
Yi-Hsiang Huang
Han-Chieh Lin
spellingShingle Kuei-Chuan Lee
Che-Chang Chan
Ying-Ying Yang
Yun-Cheng Hsieh
Yi-Hsiang Huang
Han-Chieh Lin
Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.
PLoS ONE
author_facet Kuei-Chuan Lee
Che-Chang Chan
Ying-Ying Yang
Yun-Cheng Hsieh
Yi-Hsiang Huang
Han-Chieh Lin
author_sort Kuei-Chuan Lee
title Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.
title_short Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.
title_full Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.
title_fullStr Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.
title_full_unstemmed Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.
title_sort aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description BACKGROUND & AIMS:Activation of the renin-angiotensin-system is known to play a role in nonalcoholic steatohepatitis. Renin knockout mice manifest decreased hepatic steatosis. Aliskiren is the first direct renin inhibitor to be approved for clinical use. Our study aims to evaluate the possible therapeutic effects and mechanism of the chronic administration of aliskiren in a dietary steatohepatitis murine model. METHODS:Male C57BL/6 mice were fed with a methionine and choline-deficient (MCD) diet to induce steatohepatitis. After 8 weeks of feeding, the injured mice were randomly assigned to receive aliskiren (50 mg·kg(-1) per day) or vehicle administration for 4 weeks. Normal controls were also administered aliskiren (50 mg·kg(-1) per day) or a vehicle for 4 weeks. RESULTS:In the MCD mice, aliskiren attenuated hepatic steatosis, inflammation and fibrosis. Aliskiren did not change expression of lipogenic genes but increase turnover of hepatic fat by up-regulating peroxisome proliferator-activated receptor α, carnitine palmitoyltransferase 1a, cytochrome P450-4A14 and phosphorylated AMP-activated protein kinase. Furthermore, aliskiren decreased the hepatic expression of angiotensin II and nuclear factor κB. The levels of oxidative stress, hepatocyte apoptosis, activation of Kupffer cells and hepatic stellate cells, and pro-fibrotic markers were also reduced in the livers of the MCD mice receiving aliskiren. CONCLUSIONS:Aliskiren attenuates steatohepatitis and fibrosis in mice fed with a MCD diet. Thus, the noted therapeutic effects might come from not only the reduction of angiotensin II but also the up-regulation of fatty acid oxidation-related genes.
url http://europepmc.org/articles/PMC3804600?pdf=render
work_keys_str_mv AT kueichuanlee aliskirenattenuatessteatohepatitisandincreasesturnoverofhepaticfatinmicefedwithamethionineandcholinedeficientdiet
AT chechangchan aliskirenattenuatessteatohepatitisandincreasesturnoverofhepaticfatinmicefedwithamethionineandcholinedeficientdiet
AT yingyingyang aliskirenattenuatessteatohepatitisandincreasesturnoverofhepaticfatinmicefedwithamethionineandcholinedeficientdiet
AT yunchenghsieh aliskirenattenuatessteatohepatitisandincreasesturnoverofhepaticfatinmicefedwithamethionineandcholinedeficientdiet
AT yihsianghuang aliskirenattenuatessteatohepatitisandincreasesturnoverofhepaticfatinmicefedwithamethionineandcholinedeficientdiet
AT hanchiehlin aliskirenattenuatessteatohepatitisandincreasesturnoverofhepaticfatinmicefedwithamethionineandcholinedeficientdiet
_version_ 1725137072025501696